Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advancing vaginal drug delivery.

Jennifer Merabet1, Daniel Thompson, R Saul Levinson

  • 1KV Pharmaceuticals, St. Louis, MO 63144-2555, USA. jmerabet@kvph.com

Expert Opinion on Drug Delivery
|November 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV Trial.

Blood·2026
Same author

Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.

Molecular therapy. Advances·2026
Same author

The NMR Exchange Format (NEF): Specification and Applications.

bioRxiv : the preprint server for biology·2026
Same author

Days alive and out of hospital after burr-hole drainage for chronic subdural haematoma: a national cohort study using Hospital Episode Statistics in England.

BMJ open·2026
Same author

Patterns of care and outcomes following external ventricular drain placement: Insights from the England HES administrative data set.

Brain & spine·2026
Same author

ZAP-X Stereotactic Radiosurgery: The Initial Experience Involving 200 Patients.

Cureus·2026
Same journal

Dry powder inhaler selection in COPD: integrating device design, formulation performance, and patient inspiratory capability.

Expert opinion on drug delivery·2026
Same journal

Letter to the Editor: 'saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Response to letter to the editor: 'Saving money but costing lives: the lack of integrated dose counters on pressurised metered dose inhalers'.

Expert opinion on drug delivery·2026
Same journal

Mechanism-guided metal complex therapeutics for biofilm-driven wound infections and transdermal delivery.

Expert opinion on drug delivery·2026
Same journal

Next-generation strategies for PROTAC formulation: mechanistic insights and advanced formulation technologies.

Expert opinion on drug delivery·2026
Same journal

Drug penetration in solid tumors: influence of drug size and capillary architecture.

Expert opinion on drug delivery·2026
See all related articles

A novel vaginal drug delivery system offers a single-dose treatment for common infections like bacterial vaginosis and vulvovaginal candidiasis. This new method enhances convenience and compliance compared to older, multi-day treatments.

Area of Science:

  • Gynecology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) are prevalent gynecological infections.
  • Existing treatments for BV and VVC have limitations, including systemic side effects of oral therapies and poor compliance with traditional vaginal preparations due to multi-day dosing, messy formulations, and nighttime administration.

Purpose of the Study:

  • To introduce a novel vaginal drug delivery system designed to overcome the limitations of conventional treatments.
  • To enhance patient convenience and compliance for treating common vaginal infections.

Main Methods:

  • Development of a proprietary vaginal drug delivery system with bioadhesive and sustained-release properties.
  • Application of this delivery system to two specific products: Gynazole-1 (butoconazole nitrate 2%) for VVC and Clindesse (clindamycin phosphate 2%) for BV.

Related Experiment Videos

Main Results:

  • The new delivery system enables a single-dose administration, applicable at any time.
  • Achieved efficacy rates equivalent to longer treatment durations.
  • Improved convenience and compliance for patients undergoing treatment for VVC and BV.

Conclusions:

  • The novel bioadhesive, sustained-release vaginal delivery system represents a significant advancement in treating common gynecological infections.
  • This innovation enhances therapeutic convenience and patient compliance, offering an effective alternative to traditional treatments for bacterial vaginosis and vulvovaginal candidiasis.